University of Oxford and Sound Pharmaceuticals begin Phase 2 clinical trial on novel treatment for bipolar disorder

Dr. Philip Cowen, Principal Investigator of the Oxford study is a distinguished clinician in the Department of Psychiatry. He has received numerous awards for his groundbreaking work on the psychopharmacology of mood disorders, such as bipolar illness and treatment-resistant depression. “Patients with bipolar disorder and resistant depression need additional treatment options to better manage their illness especially in the chronic phase,” said Dr. Cowen. The Stanley Medical Research Institute (SMRI), a leading funder of clinical trials involving psychiatric disease, is providing support for this UK clinical trial. “This is our first Phase 2 clinical trial with Oxford and we are honored to collaborate with Dr. Cowen and the SMRI,” said Jonathan Kil, MD, Co-Founder, CEO and CMO. For more information regarding this UK based trial please see clinicaltrials.gov and NCT03013400.

SPI is a privately held biotech in Seattle, WA developing the first medications for the prevention and treatment of hearing loss and tinnitus www.soundpharma.com. SMRI is a nonprofit organization supporting research on the causes of, and treatments for, schizophrenia and bipolar disorder. SMRI has supported more than $550 million in research in over 30 countries. Oxford University Department of Psychiatry works in close collaboration with clinical services, particularly Oxford Health NHS Foundation Trust and the Oxford University Hospitals NHS Trust. Its leading clinical and translational academics provide a link with the world-class discovery science groups working in Oxford. The Department is committed to the translation of scientific discovery into benefits for patients. Its role is to champion patients’ interests by making basic research applicable to the causes, diagnosis, and treatment of disorders and disease. The Department of Psychiatry has built expertise and extensive networks in a variety of research fields from molecular biology to brain imaging, from behavioural research to epidemiology, bringing together clinicians and scientists in all our research groups, and collaborating with leading experts in other departments and institutions.

SOURCE Sound Pharmaceuticals; The University of Oxford

Related Links

http://www.soundpharmaceuticals.com

Powered by WPeMatico

You might like

About the Author: Carrie Brunner

Carrie Brunner grew up in a small town in northern New Brunswick. She studied chemistry in college, graduated, and married her husband one month later. They were then blessed with two baby boys within the first four years of marriage. Having babies gave their family a desire to return to the old paths – to nourish their family with traditional, homegrown foods; rid their home of toxic chemicals and petroleum products; and give their boys a chance to know a simple, sustainable way of life. They are currently building a homestead from scratch on two little acres in central Texas. There’s a lot to be done to become somewhat self-sufficient, but they are debt-free and get to spend their days living this simple, good life together with their five young children. Carrie writes mostly on provincial stories.
%d bloggers like this: